Could your genes decide when you get a mammogram? major study tests personalized breast cancer screening
NCT ID NCT03672331
First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study is testing whether a breast cancer screening plan based on each woman's personal risk (using clinical factors and genetic markers) works better than the standard schedule. Over 53,000 women aged 40-70 are being randomly assigned to either risk-based or standard screening for 4 years. The goal is to see if the personalized approach reduces the number of advanced (stage 2 or higher) breast cancers detected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that tailoring screening to a woman's personal risk is better than a one-size-fits-all approach, potentially reducing advanced breast cancers.
- What could go wrong
- This is a large study, but results are not yet available. The personalized strategy may not prove superior, and risk assessment tools may not be accurate for all women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST SCREENING are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AUSL Reggio Emilia
Reggio Emilia, Emilia-Romagna, Italy
-
Assuta Medical Center Ramat HaHayal
Tel Aviv, Israel
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
-
Gustave roussy
Villejuif, France
-
Institut Jules Bordet
Brussels, Belgium
-
Marta Romản
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.